Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 7;11(11):e006885. doi: 10.1136/jitc-2023-006885

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Transcriptomic analyses from The Cancer Genome Atlas kidney papillary cell carcinoma cohort (n=271). (A) Heatmap representing unsupervised analysis from MCP-counter on normalized transcriptomic expression data (k=2), identifying the TME subtypes. (B) Boxplots representing the transcriptomic expression of five checkpoint markers according to clusters from the MCP-counter analysis. (C) Boxplots representing the three predictive gene signatures of response to treatment described in the clear-cell renal cell carcinoma (angiogenesis, effector T-cell (Eff T), JAVELIN Renal 101 Immuno), according to the clusters from MCP-counter. P values were obtained using the two-sided Mann-Whitney test (***p<0.001). (D) Kaplan-Meier survival curves (overall survival (OS)) according to clusters from MCP-counter analysis. CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; LAG-3, lymphocyte activation gene-3; MCP, Microenvironment Cell Populations; NK, natural killer; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; TIGIT, T cell immunoglobulin and ITIM domain; TME, tumor microenvironment.